Curated from medtech publications. Product launches, FDA clearances, M&A, technology shifts — rewritten as short briefs, linked back to the source. Filter by theme below.
Medtronic released real-world evidence from its registry supporting the performance of its cardiac ablation systems in patients with atrial fibrillation and ventricular tachycardia. The findings reflect clinical outcomes from deployed ablation platforms and contribute to the vendor's clinical validation portfolio for rhythm-management technologies.
St Luke's Health System has selected hellocare.ai to deploy an AI-assisted virtual care platform across its inpatient facilities in Idaho. The implementation represents a vendor adoption of digital health software for patient engagement and care delivery across multiple hospital sites.
IceCure Medical has enrolled the first two patients at two US clinical centers in the ChoICE trial evaluating its ProSense cryoablation system for treatment of low-risk breast cancer. The trial marks an early-stage clinical assessment of the company's ablation device in a breast-cancer indication.
Formacoat has introduced HydroMark™, a hydrophilic coating technology for medical devices. The coating is designed to give device manufacturers greater choice, flexibility, and supply-chain resilience in their manufacturing processes.
Spiro Medical has enrolled the first patient in its PULSAR feasibility study, which evaluates a neuromodulation device for treating severe, uncontrolled asthma. The trial marks an early-stage clinical evaluation of the company's therapeutic approach to a patient population with limited options.
Corcym presented seven-year follow-up data from its clinical study of Perceval Plus, a sutureless aortic valve, at the EACTS conference. The data demonstrated sustained cardiovascular benefit over the long-term follow-up period. Perceval Plus is used in surgical aortic valve replacement procedures.
Viome Life Sciences' clinical division Viome PRO launched CancerDetect Pancreatic, a physician-ordered blood test for detecting pancreatic ductal adenocarcinoma. The test represents a new product offering in the company's cancer diagnostics portfolio and targets early detection in a disease with historically poor prognosis.
BD announced nine-month clinical data from the AGILITY Investigational Device Exemption trial evaluating its Revello Vascular Covered Stent in the iliac vascular segment. The trial is part of BD's regulatory pathway for the device, which is designed for treatment of iliac arterial disease.
Teladoc Health launched two AI-powered features for its Solo virtual care platform: contactless vital signs monitoring and an ambient AI scribe tool. The capabilities are designed for hospitals and health systems to integrate into remote patient visits, enabling clinicians to capture vitals without physical contact and generate automated clinical documentation during telehealth encounters.
Epicore Biosystems has partnered with MECFA to develop a wearable microfluidic platform for cystic fibrosis monitoring and management. The collaboration aims to advance Epicore's wearable technology for CF patient care and disease management applications.
Medtronic's MiniMed presented data at EASD 2026 showing that type 1 diabetes patients using its Smart MDI (multiple daily injection) system who responded promptly to alerts achieved approximately 8 percentage points higher time in range compared to lower-response cohorts. The Smart MDI system provides alert functionality to support diabetes management.
Emboline completed the first two commercial US procedures using its Emboliner Embolic Protection System for transcatheter aortic valve implantation (TAVI). The device is designed to protect patients during valve replacement by capturing embolic debris. The milestone marks the system's entry into routine clinical use in the United States following regulatory clearance.
Roche Diagnostics subsidiary TIB MOLBIOL launched the LightMix Newborn TREC/SMN1/HBB, an in vitro diagnostic test kit for newborn screening. The test targets three conditions: T-cell receptor excision circles (TREC), spinal muscular atrophy (SMN1), and sickle cell disease (HBB gene).
Abbott has commercially launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening, across the United States. The test represents a non-invasive screening option in the colorectal cancer detection market.
Siemens Healthineers launched Innovance D-Dimer 2.0, a new assay for detecting blood clots, following CE mark certification and FDA 510(k) clearance. The product is now available globally for clinical laboratory use in thrombosis screening and patient management.
A fatigue-resistant wire material is enabling the development of smaller cardiac catheters with integrated sensing capabilities for electrophysiology procedures. The advancement allows for more reliable real-time data collection during EP interventions while reducing device footprint.
Revvity launched the GSP T1D 3plex kit, a diagnostic product designed to screen children for type 1 diabetes risk before symptom onset. The kit supports population screening programs by enabling early detection of autoimmune markers associated with T1D development.
Xella Health announced an integration with ŌURA to create a connected precision health platform tailored for women's health management. The partnership combines both companies' capabilities to deliver personalized health monitoring and insights based on women's biological data.
Precision Diabetes and DirectSens have partnered to commercialize the MetMark clinical test in the US. The test measures AHB and 2-HB biomarkers associated with metabolic dysfunction and type 2 diabetes risk. The collaboration marks the US market entry for this diagnostic offering.
Pelago launched a behavioral health platform integrating substance use disorder, mental health, and behavioral addiction care management. The platform uses AI-powered triage to match patients with appropriate treatment resources. The offering targets healthcare providers and systems managing behavioral health populations.
Hyperfine announced completion of patient enrolment in its multi-centre Contrast PMR study evaluating contrast agents with its Swoop portable MRI system. The study completion marks progress toward expanded clinical applications for the point-of-care MRI device.
Dr. Claudia Chavez-Munoz, co-founder and Chief Scientific Officer of Conexeu Sciences, has developed a regenerative, bioabsorbable extracellular matrix (ECM) platform for personalized breast implants, burn wound care, and tissue restoration. The technology addresses limitations in existing acellular implant solutions and leverages bioprinting to enable customized implants across multiple surgical applications.
Aerotech announced the LaserTurn280, a motion platform designed for high-volume laser machining of cylindrical medical-device components used in coronary stents, neurovascular stents, structural heart devices, peripheral vascular implants, and minimally invasive surgical instruments. The system was previously shown in prototype form at medical-technology trade shows.
Nightingale Health and Genom have partnered to launch a blood-based risk detection test in Croatian clinics and laboratories. The test leverages biomarker analysis to identify disease risk in patient populations. The partnership expands Nightingale's diagnostic footprint in Central Europe through Genom's local laboratory network.
Petal Surgical CEO Prash Chopra previewed the company's incisionless surgery system combining histotripsy ablation, robotics, and AI, ahead of an expected first-in-human procedure. The technology targets millimeter-scale tissue destruction without incisions, representing a potential shift in minimally invasive surgical approaches.
restor3d launched MyFit, a digital platform designed to enhance patient engagement and visibility throughout orthopaedic care pathways. The suite targets orthopaedic care providers and patients seeking integrated care management and communication tools.
nPhase, a clinical research technology vendor, launched nPhase.AI, an AI-native enterprise platform for end-to-end clinical data management. The platform includes an agentic statistical computing environment designed to reduce time from raw study data to submission-ready outputs by 75% while requiring 80% fewer resources.
LEP Biomedical is developing a dissolvable implant designed to replace post-operative eye drops following glaucoma surgery. The device aims to improve patient compliance during recovery, addressing a significant driver of surgical failure rates that can reach 40%. The implant delivers medication over weeks without requiring patient self-administration.
Nyxoah, a Belgium-based medical device company, has implanted the first patient in its BREATHE post-approval study of the Genio system for obstructive sleep apnea. The Genio is an implantable neurostimulation device designed to treat OSA by stimulating the hypoglossal nerve.
Philips launched the eV14-2v transvaginal transducer, expanding its ultrasound portfolio for obstetrics and gynecology applications. The transducer is designed for use in reproductive health imaging procedures.
HR HealthCare launched the Liv Pre-lubricated Intermittent Catheter, a device designed for female self-catheterization to support bladder health management. The product addresses a specific segment of the intermittent catheterization market with pre-lubricated technology.
Selio Medical announced FDA clearance for a hydrogel device designed to seal puncture sites during CT-guided lung biopsies, preventing pneumothorax complications that occur in up to one-third of the 800,000+ procedures performed annually in the U.S. The device addresses a significant clinical and economic burden associated with this common diagnostic procedure.
Abbott presented longer-term clinical data for its TactiFlex Duo ablation catheter at ESC 2026, a dual-modality device combining pulsed-field and radiofrequency ablation for atrial fibrillation treatment. The data demonstrated positive outcomes with the dual-technology approach, which offers clinicians flexibility in catheter selection during AF procedures.
Fractyl Health's Revita system, a minimally invasive hydrothermal ablation device, demonstrated efficacy in maintaining up to 84% of weight loss achieved with GLP-1 medications one year after discontinuation. The single-use catheter targets the duodenal mucosa in the proximal small intestine. The device represents a potential adjunctive approach to weight management following GLP-1 therapy cessation.
Heartflow presented data at ESC 2026 showing its fractional flow reserve (FFR) technology reduced unnecessary invasive coronary angiography (ICA) by 44% at one year, compared to 22% reduction with coronary CT angiography (CCTA) alone. The tool integrates with existing imaging workflows to guide intervention decisions in coronary artery disease assessment.
Philips and Imricor Medical Systems launched a new iMR lab solution designed for cardiac interventions. The system integrates MR imaging with interventional capabilities to support real-time guidance during cardiac procedures, combining Philips' imaging platform with Imricor's MR-compatible cardiac technology.
Datavant launched a provider exchange platform designed to digitize medical record requests, replacing traditional fax-based workflows. The system provides real-time visibility into request status and reduces administrative burden on clinical staff by accelerating retrieval from days to hours.
Axoft has launched Fleuron WISE, a polymer designed to reduce optical distortions during high-resolution imaging of aqueous biological samples. The material targets improved image quality in microscopy and diagnostic imaging applications where sample clarity is critical.
Medical Guardian launched Guardian Flex, a wearable device designed for older adults that provides emergency alert capabilities. The product integrates into daily routines and targets the aging population seeking personal safety and emergency response solutions.
Researchers at UC San Diego developed a wearable smart ring that uses finger sweat to monitor six biomarkers: glucose, ketones, vitamin C, uric acid, lactate, and alcohol. The device employs an osmotic hydrogel to extract and analyze sweat composition, with findings published in Nature Communications. The technology represents a new class of non-invasive continuous monitoring wearable for personal health tracking.
111 older new products stories available.